Health & Fitness
Mon, October 1, 2012Sun, September 30, 2012Sat, September 29, 2012Fri, September 28, 2012Thu, September 27, 2012Wed, September 26, 2012Tue, September 25, 2012Mon, September 24, 2012Sun, September 23, 2012Fri, September 21, 2012Thu, September 20, 2012Wed, September 19, 2012Tue, September 18, 2012Mon, September 17, 2012Uroplasty To Participate In The Craig-Hallum Alpha Select Conference
//health-fitness.news-articles.net/content/2012/ .. in-the-craig-hallum-alpha-select-conference.html
Published in Health and Fitness on Tuesday, September 25th 2012 at 9:46 GMT by Market Wire🞛 This publication is a summary or evaluation of another publication
Uroplasty To Participate In The Craig-Hallum Alpha Select Conference -- MINNEAPOLIS, Sept. 25, 2012 /PRNewswire/ --
Uroplasty To Participate In The Craig-Hallum Alpha Select Conference
MINNEAPOLIS, Sept. 25, 2012 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: [ UPI ]), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced its participation in the Craig-Hallum Alpha Select Conference on Thursday, September 27, 2012. David Kaysen, President and CEO, and Medi Jiwani, Chief Financial Officer, will present and meet with investors one on one at the conference in New York City.
Attendance at the conference is by invitation only. The presentation and the meetings will not be webcast.
About Uroplasty, Inc.
Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom is a global medical company committed to offering transformative treatment options to specialty physicians. Our products are designed to help providers change the lives of their voiding dysfunction patients and strengthen the efficiency of their practices. Our focus is the continued commercialization of our Urgent® PC Neuromodulation System, the only FDA-cleared system that delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence. We also offer Macroplastique®, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at [ www.uroplasty.com ].
For Further Information: | |
Uroplasty, Inc. | EVC Group |
David Kaysen, President and CEO, or | Doug Sherk/Jenifer Kirtland (Investors), 415.568.9349 |
Medi Jiwani, Vice President, CFO, Treasurer | Chris Gale (Media), 646.201.5431 |
952.426.6140 |
SOURCE Uroplasty, Inc.
[ Back to top ]
RELATED LINKS
[ http://www.uroplasty.com ]